Editas Medicine Inc is at the forefront of genome editing, pioneering treatments for serious diseases using CRISPR technology. With a focus on developing genomic medicines, its leading projects include EDIT-101 for a rare eye disease and reni-cel for sickle cell disease and beta-thalassemia. The company also explores cancer treatments through engineered T cells. Founded in 2013 and based in Cambridge, Massachusetts, Editas collaborates with industry leaders to advance its mission of transforming medicine.
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
There has been a noticeable shift in the stock market over the last two months. Investors are moving away from former high-flying large- and mega-cap stocks into discounted small-cap names that the…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Thursday's top analyst upgrades and downgrades included Albemarle, Arm, CrowdStrike, Dow, Fortinet, Hudson Pacific Properties, Lithium Americas, LyondellBasell Industries, Match, Palo Alto Networks, Pinterest, Sibanye-Stillwater, Uber Technologies and Vestis.
Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk, Valvoline and Walmart.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, American Eagle Outfitters, Azek, Bausch Health, Coinbase Global, Dell Technologies, Fidelity National Information Services, Invesco, Marathon Petroleum, Netflix, New Residential Investment, Spotify…
Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Caesars Entertainment, Coinbase Global, Editas Medicine and Wynn Resorts.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Bath & Body Works, Editas Medicine, GoDaddy, PetMed Express and Qorvo.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
